Infectious Disease Topics
RSSArticles
-
Syphilis RPR May Fluctuate Before Treatment
The more time between testing and treatment, the more likely the change in the titer. Since patients often are called back for treatment, these data suggest clinicians should obtain a repeat rapid plasma reagin at the time these patients return for treatment, effectively establishing a new baseline.
-
Biden Announces Choice for New CDC Director
Mandy Cohen will succeed Rochelle Walensky, who will step down at the end of June.
-
Infectious Disease Alert Updates
Head and Neck Cancer Worse in HIV; Syphilis RPR May Fluctuate Before Treatment
-
Induction Therapy for HIV/AIDS-Related Disseminated Histoplasmosis with Single High-Dose Liposomal Amphotericin B
In a Phase II randomized clinical trial involving 118 participants in Brazil with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS)-related disseminated histoplasmosis, induction therapy with single high-dose (10 mg/kg) liposomal amphotericin B was safe and non-inferior as compared with standard dose (3 mg/kg) liposomal amphotericin B given once daily for 14 days.
-
Vaccination Against Mpox Is Effective
Two-dose vaccination with Jynneos is effective in the prevention of mpox (monkeypox), but a better vaccine is desirable, particularly for use in immunocompromised individuals.
-
Bird Flu: Is It Becoming a Threat to Humans?
A strain of influenza A virus that is highly pathogenic for birds is capable of infecting humans for whom it poses a potential risk as it continues to evolve and spread.
-
Mothers, Babies, and HPV: Thanks for Not Sharing!
Nearly half of pregnant women in a Canadian study had vaginal swabs positive for human papillomavirus (HPV) deoxyribonucleic acid (DNA). Only about one-fourth of placentas and newborns produced by those HPV-positive women carried detectable HPV DNA, and all HPV-positive babies had cleared their positivity by 6 months of age.
-
Scientists Use Artificial Intelligence While Searching for ‘Superbug’ Solutions
Researchers enlisted the help of technology to find an antibiotic that could fight multidrug-resistant bacteria.
-
Respiratory Syncytial Virus Vaccine, Adjuvanted (Arexvy)
Arexvy can be administered to prevent lower respiratory tract disease caused by respiratory syncytial virus in patients age 60 years and older.
-
Infectious Disease Alert Updates
Immunocompromised Patients with Persistent COVID-19; Endemic Mycoses Are No Longer ‘-Demic’